Literature DB >> 16160762

DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.

Yolanda Morera-López1, Josep Maria Torres-Rodríguez, Teresa Jiménez-Cabello, Teresa Baró-Tomás, Concepción Alía-Aponte, Marcia S Lázera.   

Abstract

Cryptococcus neoformans var. grubii (serotype A) was isolated from 12 soil samples mixed with pigeon droppings (16.9%) from 71 soil samples in Barcelona and rural areas of Catalonia. C. neoformans was not isolated from indoor dust and Eucalyptus debris. PCR fingerprinting was performed in 22 representative isolates and all of them corresponded to the VNI pattern. Susceptibility testing for the 22 isolates of C. neoformans var. grubii showed that all of them were susceptible to amphotericin B. Three isolates presented MICs (Minimal Inhibitory Concentrations) > or = 1 microg/ml to Itraconazole, five MICs > or = 1 microg/ml to ketoconazole and four were fluconazole resistant, (MICs > or = 64 microg/ml), while three of them were shown to have MICs > or = 1 microg/ml to voriconazole. In spite that all isolates presented the same DNA fingerprinting pattern, the susceptibility to antifungals is very variable. The possibility of acquiring cryptococcosis infection with primarily resistant environment strains is feasible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160762     DOI: 10.1007/s11046-005-6332-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  18 in total

1.  [First local case of human cryptococcosis in Spain caused by Cryptococcus neoformans var. gattii].

Authors:  María Francisca Colom; Susana Frasés; Consuelo Ferrer; Alejandro Jover; Mariano Andreu; José María Torres-Rodríguez
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

2.  First identification of autochthonous Cryptococcus neoformans var. gattii isloated from goats with predominantly severe pulmonary disease in Spain.

Authors:  T Baró; J M Torres-Rodríguez; M H De Mendoza; Y Morera; C Alía
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Authors:  P Mondon; R Petter; G Amalfitano; R Luzzati; E Concia; I Polacheck; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey.

Authors:  W Meyer; K Marszewska; M Amirmostofian; R P Igreja; C Hardtke; K Methling; M A Viviani; A Chindamporn; S Sukroongreung; M A John; D H Ellis; T C Sorrell
Journal:  Electrophoresis       Date:  1999-06       Impact factor: 3.535

5.  The brown colour effect (BCE) of Cryptococcus neoformans in the diagnosis, control and epidemiology of C. neoformans infections in AIDS patients.

Authors:  F Staib; M Seibold; E Antweiler; B Fröhlich; S Weber; A Blisse
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-08

6.  [Disseminated cryptococcosis in patients with AIDS. Prognostic factors of poor outcome].

Authors:  M Alonso; F García; J Mallolas; A Soriano; M Ortega; J M Miró; J M Gatell; E Soriano
Journal:  Med Clin (Barc)       Date:  1999-03-27       Impact factor: 1.725

7.  In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.

Authors:  M H Nguyen; C Y Yu
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Molecular typing of IberoAmerican Cryptococcus neoformans isolates.

Authors:  Wieland Meyer; Alexandra Castañeda; Stuart Jackson; Matthew Huynh; Elizabeth Castañeda
Journal:  Emerg Infect Dis       Date:  2003-02       Impact factor: 6.883

10.  In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.

Authors:  S P Franzot; J S Hamdan
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more
  1 in total

1.  Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.

Authors:  C S Matos; A de Souza Andrade; N S Oliveira; T F Barros
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-26       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.